Verastem (NASDAQ:VSTM) Given “Outperform” Rating at Royal Bank of Canada

Verastem (NASDAQ:VSTM – Get Rating)‘s stock had its “outperform” rating reiterated by stock analysts at Royal Bank of Canada in a report released on Wednesday, Benzinga reports. They currently have a $3.00 price target on the biopharmaceutical company’s stock.

Several other equities research analysts also recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Verastem in a research note on Wednesday. StockNews.com started coverage on shares of Verastem in a research report on Friday, March 10th. They set a “hold” rating for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $4.25.

Verastem Price Performance

NASDAQ VSTM opened at $0.45 on Wednesday. The firm’s fifty day simple moving average is $0.56 and its two-hundred day simple moving average is $0.58. The company has a current ratio of 4.97, a quick ratio of 4.97 and a debt-to-equity ratio of 0.39. Verastem has a 12-month low of $0.29 and a 12-month high of $2.13. The firm has a market capitalization of $94.96 million, a P/E ratio of -1.10 and a beta of 0.81.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Merit Financial Group LLC raised its position in shares of Verastem by 229.2% in the fourth quarter. Merit Financial Group LLC now owns 65,846 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 45,846 shares during the period. Eaton Vance Management acquired a new position in shares of Verastem in the first quarter worth about $28,000. Financial Advisors LLC acquired a new position in shares of Verastem in the second quarter worth about $35,000. Mirabella Financial Services LLP purchased a new stake in shares of Verastem during the first quarter worth about $36,000. Finally, XTX Topco Ltd purchased a new stake in shares of Verastem during the first quarter worth about $37,000. Institutional investors and hedge funds own 60.59% of the company’s stock.

Verastem Company Profile

(Get Rating)

Verastem, Inc is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.